Eric Sung

Company: Fate Therapeutics
Job title: Associate Scientist – In Vivo Pharmacology
Seminars:
Discussion/Q&A 10:40 am
day: Day Two
In Vivo Screens in Mouse Tumor Models Treated with Pools of Edited CAR-T Cells to Identify the Next Generation of iPSC Derived Immunotherapies for Cancer 9:00 am
Introduction to Fate’s iPSC Derived Immunotherapy Platform Novel multiplexed approach to generate pools of engineered CAR-T clones with different edits for combinatorial testing in vitro and in vivo Using genomics to screen pools of edited CAR-T in mouse tumor models to identify winning clones with specific editsRead more
day: Day Two